1. US Food and Drug Administration, Division of Marketing, Advertising, and Communications. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm. Accessed September 3, 2010.
2. US Food and Drug Administration. Warning letters and notice of violation letters to pharmaceutical companies. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Enforcement ActivitiesbyFDA/WarningLettersandNoticeofViolationLettersto-PharmaceuticalCompanies/default.htm. Accessed May 17, 2011.
3. Bonk L, Kothari M. How pharmaceutical companies handle promotional review: a benchmarking survey. Presented at DIA Annual Workshop in Medical Communications; March 15–17, 2010; Scottsdale, AZ.
4. Sous A, Noormohamed SE, Nadal J. Medical information depart-ment: the medical review of promotional materials across pharma-ceutical companies. Presented at DIA Annual Workshop in Medical Communications; March 15–17, 2010; Scottsdale, AZ.
5. Yang E, Fung S. Medical communications involvement in promo-tional review. Presented at DIA Annual Workshop in Medical Communications; March 15–17, 2010; Scottsdale, AZ.